Morningstar

Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation | Morningstar

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced clinical data ...
Seeking Alpha

Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) ...
Healio

Newer pulsed field ablation ‘already as effective’ as radiofrequency ablation

Please provide your email address to receive an email when new articles are posted on . AF recurrence after pulsed field ablation was comparable vs. after radiofrequency ablation. There were fewer ...
Healio

Pulsed field ablation as first-line treatment superior to drug therapy in persistent AF

Please provide your email address to receive an email when new articles are posted on . In patients with persistent AF, pulsed field ablation was better than drug therapy at preventing arrhythmia ...
Post-Bulletin

Mayo Clinic Q&A: What is pulsed field ablation?

DEAR MAYO CLINIC: I have atrial fibrillation, and I've heard there's a new kind of ablation that could relieve my symptoms. Can you tell me about it? ANSWER: If you have atrial fibrillation (AFib), ...
Business Wire

Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) ...